China Universal Asset Management Company’s Sutro Biopharma STRO Stock Holding History

China Universal Asset Management Company’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,486	Closed	-$12.9K	–	528
2025 Q3	$12.9K	Sell	1,486 -210	-12%	-$1.79K	﹤0.01%	468
2025 Q2	$12.1K	Buy	1,696 +42	+3%	+$343	﹤0.01%	464
2025 Q1	$10.8K	Sell	1,654 -94	-5%	-$1.48K	﹤0.01%	477
2024 Q4	$32.2K	Buy	+1,748	New	+$53.4K	﹤0.01%	471
2023 Q4	–	Sell	-155	Closed	-$5.37K	–	479
2023 Q3	$5.37K	Buy	155 +76	+96%	+$3.31K	﹤0.01%	384
2023 Q2	$3.68K	Buy	79 +1	+1%	+$50	﹤0.01%	397
2023 Q1	$3.6K	Buy	78 +20	+34%	+$1.27K	﹤0.01%	400
2022 Q4	$4.71K	Buy	58 +9	+18%	+$625	﹤0.01%	305
2022 Q3	$3K	Buy	+49	New	+$2.9K	﹤0.01%	336

Other funds holding STRO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

China Universal Asset Management Company's STRO Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 1,486 shares — an estimated $12.9K sold.

China Universal Asset Management Company first reported a position in STRO in Q3 2022 and held it in 9 quarters. The position peaked at $32.2K in Q4 2024. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

China Universal Asset Management Company reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 1,486 Sutro Biopharma shares in Q4 2025, an estimated $12.9K.
China Universal Asset Management Company first reported a position in Sutro Biopharma in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Sutro Biopharma position peaked at $32.2K in Q4 2024.
63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.